Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1840485 | 1.00 | TSHR (0.36) | TSHRCYP2C19USP2ALDH1A1LMNA | |
| SCHEMBL2832088 | 1.00 | TSHR (0.36) | TSHRCYP2C19USP2ALDH1A1LMNA | |
| SCHEMBL2827340 | 0.97 | TSHR (0.32) | TSHRCYP2C19USP2ALDH1A1LMNA | |
| SCHEMBL2833245 | 0.92 | — | — | |
| SCHEMBL873141 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL11029381 | 0.84 | — | — | |
| SCHEMBL715609 | 0.82 | TSHR (0.37) | TSHRCYP2C19USP2ALDH1A1LMNA | |
| SCHEMBL1935525 | 0.80 | TSHR (0.36) | TSHRCYP2C19USP2ALDH1A1LMNA | |
| SCHEMBL2192555 | 0.80 | TSHR (0.36) | TSHRCYP2C19USP2ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL11579187 | 0.78 | TSHR (0.34) | TSHRCYP2C19USP2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3891176-B1 | DUAL AGONIST GLP-1 AND NEUROTENSIN FUSION PEPTIDE | HOLST BIRGITTE (DK) | 2024-06-05 | — | — | EP | claimed |
| EP-3250191-B1 | TABLETS COMPRISING GLP-1 AGONIST AND ENTERIC COATING | NOVO NORDISK AS (DK) | 2024-01-17 | — | — | EP | claimed |
| EP-2637698-B1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK AS (DK) | 2022-04-20 | — | — | EP | claimed |
| EP-2932981-B1 | Albumin-binding derivatives of GLP-1 | NOVO NORDISK AS (DK) | 2021-06-16 | — | — | EP | claimed |
| EP-3225631-B1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK AS (DK) | 2019-01-09 | — | — | EP | claimed |
| EP-2190872-B1 | GLUCAGON-LIKE PEPTIDE-1 DERIVATIVES AND THEIR PHARMACEUTICAL USE | NOVO NORDISK AS (DK) | 2018-03-14 | — | — | EP | claimed |
| EP-2846824-B1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK AS (DK) | 2017-04-05 | — | — | EP | claimed |
| EP-2753642-B1 | GLP-1 DERIVATIVES | NOVO NORDISK AS (DK) | 2017-03-01 | — | — | EP | claimed |
| EP-2696687-B1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK AS (DK) | 2016-10-26 | — | — | EP | claimed |
| EP-2190873-B1 | TRUNCATED GLP-1 DERIVATIVES AND THEIR THERAPEUTICAL USE | NOVO NORDISK AS (DK) | 2015-07-22 | — | — | EP | claimed |
| EP-1863521-B1 | EXTENDED GLP-1 COMPOUNDS | NOVO NORDISK AS (DK) | 2014-05-07 | — | — | EP | claimed |
| EP-2045265-B1 | GLP-1 (Glucagon-like peptide-1) fusion polypeptides with increased peptidase resistance | BIOCOMPATIBLES UK LTD (GB) | 2012-11-21 | — | — | EP | claimed |
| EP-1926748-B1 | GLP-1 ( GLUCAGON-LIKE PEPTIDE-1 ) FUSION POLYPEPTIDES WITH INCREASED PEPTIDASE RESISTANCE | BIOCOMPATIBLES UK LTD (GB) | 2012-08-29 | — | — | EP | claimed |
| EP-1863839-B1 | ACYLATED GLP-1 COMPOUNDS | NOVO NORDISK AS (DK) | 2010-08-04 | — | — | EP | claimed |
| EP-1704165-B1 | GLP-1 COMPOUNDS | NOVO NORDISK AS (DK) | 2010-03-17 | — | — | EP | claimed |
| EP-1767545-B1 | GLP-1 (Glucagon-like peptide-1) fusion polypeptides with increased peptidase resistance | BIOCOMPATIBLES UK LTD (GB) | 2009-11-11 | — | — | EP | claimed |